tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

DE:XRP2 Stock Latest News

Silence Therapeutics Passes Key Resolutions at AGM
Company AnnouncementsSilence Therapeutics Passes Key Resolutions at AGM
5d ago
8K
SLN
Buy Rating on Silence Therapeutics: Promising Developments in Divesiran and Zerlasiran Programs
PremiumRatings
Buy Rating on Silence Therapeutics: Promising Developments in Divesiran and Zerlasiran Programs
19d ago
SLN
Promising Phase 1 Data and Strong Mechanistic Rationale Justify Buy Rating for Silence Therapeutics’ Divesiran in Polycythemia Vera
PremiumRatings
Promising Phase 1 Data and Strong Mechanistic Rationale Justify Buy Rating for Silence Therapeutics’ Divesiran in Polycythemia Vera
19d ago
SLN
Positive Outlook for Silence Therapeutics: Promising Clinical Data and Progress in SANRECO Study Justify Buy Rating
PremiumRatings
Positive Outlook for Silence Therapeutics: Promising Clinical Data and Progress in SANRECO Study Justify Buy Rating
19d ago
SLN
Silence Therapeutics presents additional Phase 1 data highlighting Divesiran
PremiumThe Fly
Silence Therapeutics presents additional Phase 1 data highlighting Divesiran
19d ago
SLN
Silence Therapeutics Reports Q1 2025 Financial Results
PremiumCompany AnnouncementsSilence Therapeutics Reports Q1 2025 Financial Results
2M ago
SLN
Silence Therapeutics: Strategic Positioning and Growth Potential Justify Buy Rating
Premium
Ratings
Silence Therapeutics: Strategic Positioning and Growth Potential Justify Buy Rating
2M ago
SLN
Silence Therapeutics reports Q1 EPS (20c), consensus (41c)
Premium
The Fly
Silence Therapeutics reports Q1 EPS (20c), consensus (41c)
2M ago
SLN
Silence Therapeutics Announces Board Changes and New Director
PremiumCompany Announcements
Silence Therapeutics Announces Board Changes and New Director
2M ago
8K
SLN
Silence Therapeutics: Strategic Focus and Strong Financials Poised for Growth with Promising RNAi Pipeline
PremiumRatings
Silence Therapeutics: Strategic Focus and Strong Financials Poised for Growth with Promising RNAi Pipeline
4M ago
SLN
Silence Therapeutics Plc Earnings Call Highlights Progress and Challenges
PremiumCompany Announcements
Silence Therapeutics Plc Earnings Call Highlights Progress and Challenges
4M ago
SLN
Strategic Focus and Market Opportunities Drive Buy Rating for Silence Therapeutics
PremiumRatings
Strategic Focus and Market Opportunities Drive Buy Rating for Silence Therapeutics
4M ago
SLN
Silence Therapeutics Reports 2024 Financial Results and Strategic Focus
PremiumCompany AnnouncementsSilence Therapeutics Reports 2024 Financial Results and Strategic Focus
4M ago
SLN
Silence Therapeutics Extends Cash Runway to 2027
Premium
Company Announcements
Silence Therapeutics Extends Cash Runway to 2027
4M ago
8K
SLN
Silence Therapeutics price target lowered to $30 from $31 at Jefferies
Premium
The Fly
Silence Therapeutics price target lowered to $30 from $31 at Jefferies
4M ago
SLN
Silence Therapeutics reports FY25 net loss 33c vs. 49c loss last year
PremiumThe Fly
Silence Therapeutics reports FY25 net loss 33c vs. 49c loss last year
4M ago
SLN
Silence Therapeutics extends projected cash runway into 2027
PremiumThe Fly
Silence Therapeutics extends projected cash runway into 2027
4M ago
SLN
Buy/Sell: Wall Street’s top 10 stock calls this week
PremiumThe Fly
Buy/Sell: Wall Street’s top 10 stock calls this week
5M ago
KHC
PCG
Sell Rating on Silence Therapeutics Due to Suboptimal Dosing, Financial Constraints, and Competitive Lag
PremiumRatings
Sell Rating on Silence Therapeutics Due to Suboptimal Dosing, Financial Constraints, and Competitive Lag
5M ago
SLN
Goldman starts Silence Therapeutics at Sell on ‘undifferentiated’ data
PremiumThe FlyGoldman starts Silence Therapeutics at Sell on ‘undifferentiated’ data
5M ago
SLN
Silence Therapeutics initiated with a Sell at Goldman Sachs
Premium
The Fly
Silence Therapeutics initiated with a Sell at Goldman Sachs
5M ago
SLN
Silence management enthusiastic ahead of catalysts, says H.C. Wainwright
Premium
The Fly
Silence management enthusiastic ahead of catalysts, says H.C. Wainwright
5M ago
SLN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >